Biologic therapeutic proteins can trigger anti-drug antibodies (ADA), including neutralizing antibodies (NAb), which may reduce treatment effectiveness or cause adverse effects. NAbs interfere by blocking drug-target binding or neutralizing biological activity, while non-neutralizing antibodies (non-NAb) bind without affecting pharmacodynamic activity. Monitoring NAb levels during drug development is crucial for interpreting efficacy and safety, as well as preventing loss of therapeutic benefit. Specialized assays, such as SHIKARI® T-CAP NAb assays, are used to detect and measure neutralizing antibodies by assessing drug-target binding competition.
Therapeutic drug monitoring (TDM) is an important tool to ensure consistent drug levels in patients’ bloodstreams, improving efficacy, safety, and adherence while reducing drug interactions and toxicity risks. As patents for early biologics expire, biosimilars—highly similar but not identical alternatives—are increasingly available. However, due to the complex manufacturing processes, exact copies cannot be made, and even small changes may alter immunogenicity, potentially leading to unwanted immune responses, loss of effect, or adverse events. Careful monitoring and evaluation are therefore essential for both biologics and their biosimilars.
This product is manufactured in Turkey by Matriks Biotek.
| Size | 1 x 96 Well |
| Sensitivity | 20 ng/mL |
| Dynamic Range | cut-off |
| Incubation Time | 140 minutes |
| Sample Type | Serum, Plasma |
| Storage | 2-8°C |